Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare”) (NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostic company, today announced its results for the quarter ended September 30, 2026. Thyrocare reported consolidated revenue of INR 270.8 Cr in Q2FY27, up 25.1% year-on-year, driven primarily by a 26.7% increase in the Pathology segment.

Key Financial Highlights

Consolidated revenue registered a 25.1% year-on-year growth, driven primarily by a 26.7% increase in the Pathology segment. The exceptional item represents a one-time, non-cash impairment charge of Rs 45 Cr relating to NHL in consolidated books, recognised in connection with the definitive term sheet for the sale of the NHL business. This charge does not impact the Company’s operational performance.

Operational Performance

Thyrocare processed 61.6 million tests in Q2FY27, marking a strong 27.4% year-on-year growth and reinforcing its volume leadership position in the industry. The Pathology business maintained strong traction, with franchise revenue up 26.9% and partnership revenue up 27.9% year-on-year. Thyrocare’s commitment to quality continued to deliver Six Sigma-level performance, with complaints reduced to 2.9 per million (down 24% YoY) and an average turnaround time (ATAT) of 3.49 hours from sample receipt.

Future Outlook

Thyrocare continued its expansion into specialty diagnostics, marking the next phase of its growth journey. Having commenced with allergy and genomics, the Company is progressively expanding its specialty test portfolio, with a focus on building clinical trust through scientific rigour, uncompromising quality, and industry-leading turnaround times.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Thyrocare Technologies Limited

Thyrocare Technologies Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Thyrocare gains 42.8% over three months and trades near its 52-week highs. The business compounds revenue at 16.7% and profits at 36.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 87% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 16.7%, profits at 36.2%, and the PEG sits at 1.41 — below its growth rate. That combination is rare. Check Fundamentals of Thyrocare Technologies Limited.

Max India Limited (MAXIND) has announced the completion of 200 homes at its Noida senior living community, Antara Noida, marking a significant milestone. The handover of these homes within less than two months of beginning the possession process underscores the company’s commitment to its integrated approach to senior living.

Integrated Senior Living Approach

Antara Senior Care, the senior-care business of Max India Limited, has completed the handover of 200 apartments at Antara Noida, its senior-living residential community in Sector 150, Noida. This achievement highlights the company’s dedication to providing a comprehensive ecosystem that combines purpose-designed residences with wellness, care, and lifestyle services.

Commitment to Senior Independence

Rajit Mehta, Managing Director & CEO of Antara Senior Living Limited and Max India, emphasized the company’s belief in senior living as more than just a place to live. ‘We believe that senior living should be about having the freedom to live life on one’s own terms, with the confidence that care and support are always within reach,’ said Mehta. The completion of 200 homes signifies a crucial step in this journey, reinforcing the company’s mission to build communities where seniors feel supported, inspired, and empowered.

Antara Noida, located in Sector 150, Noida, is a senior-living community with a total of 340 units designed to create an ecosystem where care evolves with the changing needs of seniors. The community aims to support seniors’ independence, wellbeing, and social connection through a blend of thoughtfully curated life care and lifestyle offerings.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max India Limited

Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 13.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.

Senores Pharmaceuticals Limited (SENORES) announced its unaudited financial results for the quarter and half year ended 30th September 2026, showcasing robust financial and operational performance. The company reported a 25% year-on-year increase in revenue for Q2 FY27 and a 38% rise in EBITDA, marking consistent strong growth across its businesses.

Segmental Highlights

The company’s revenue for Q2 and H1 FY27 grew by 25% and 30% respectively on a year-on-year basis. Notably, the Regulated Markets segment saw a 34% increase in revenue, while the Emerging Markets segment grew by 21% in Q2 and 25% in H1 FY27. The company’s portfolio in Regulated Markets nearly doubled, expanding from 34 ANDAs as of September 2025 to 64 ANDAs as of September 2026, with 23 commercialized products.

Operational Excellence

Despite initial set-up and operating costs associated with Zoraya and Amerisyn, EBITDA for Q2 and H1 FY27 grew by 38% and 58% respectively, with margin expansion of approximately 290 bps and 530 bps on a year-on-year basis. The company’s cash from operations stood at ₹38 crores in H1 FY27, reflecting a consistent improvement in cash flow generation.

Forward-Looking Outlook

Senores Pharmaceuticals Limited remains optimistic about its future growth trajectory, on track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27. The company’s robust product pipeline, expanded manufacturing capabilities, and strong commercial launch visibility underpin its positive outlook for the year and beyond.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Senores holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.33 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 159.1% and profits at 139.2% CAGR. Both numbers are exceptional. The stock holds at 69% of its 52-week range with RSI at 44. In other words, neither side has a clear edge right now. Both the business and the stock move in the right direction. Revenue grows at 159.1%, profits at 139.2%, and the PEG sits at 0.33 — below its growth rate. That combination is rare. Check Fundamentals of Senores Pharmaceuticals Limited.